Datopotamab deruxtecan (solution)

Synonyms: DS-1062 (solution); Dato-DXd (solution)
Datopotamab deruxtecan (DS-1062) solution 是一种靶向 TROP2 的抗体-活性分子偶联物 (ADC),与人源 TROP2 的 Kd 为 0.74 nmol/L,由抗体 Datopotamab (MS-Q94110) 和毒性分子-连接子偶联物 Deruxtecan (MS-M03436) 组成,可结合 TROP2 并触发内化和溶酶体转运过程、释放拓扑异构酶 I 抑制剂载荷 DXd,进而破坏 DNA 功能、诱导 DNA 损伤和细胞凋亡 (apoptosis),同时对肿瘤微环境细胞产生旁观者杀伤效应,可用于三阴性乳腺癌、胃癌和非小细胞肺癌的相关研究。
产品编号: MS-Y70066 纯度: 99.98% CAS No.: 2238831-60-0
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价

产品描述

Datopotamab deruxtecan (DS-1062) solution 是一种靶向 TROP2 的抗体-活性分子偶联物 (ADC),与人源 TROP2 的 Kd 为 0.74 nmol/L,由抗体 Datopotamab (MS-Q94110) 和毒性分子-连接子偶联物 Deruxtecan (MS-M03436) 组成,可结合 TROP2 并触发内化和溶酶体转运过程、释放拓扑异构酶 I 抑制剂载荷 DXd,进而破坏 DNA 功能、诱导 DNA 损伤和细胞凋亡 (apoptosis),同时对肿瘤微环境细胞产生旁观者杀伤效应,可用于三阴性乳腺癌、胃癌和非小细胞肺癌的相关研究。

生物实验数据

生物活性 Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeting antibody-active molecule conjugate (ADC) with a Kd of 0.74 nmol/L for human TROP2, composed of the antibody Datopotamab (MS-Q94110) and the toxic molecule-linker conjugate Deruxtecan (MS-M03436); it binds TROP2 to trigger internalization and lysosomal trafficking and release the topoisomerase I inhibitor payload DXd, thereby disrupting DNA function, inducing DNA damage and apoptosis (apoptosis) while exerting a bystander killing effect on tumor microenvironment cells, and can be used for research on triple-negative breast cancer, gastric cancer, and non-small cell lung cancer.
IC50 & Target BxPC-3 cells (Trop2-expressing):74.6 ng/mL, TROP2-over expressing HGSOC cells viability:0.49 µM, CFPAC-1 cells (Trop2-expressing):706 ng/mL, HGSOC cells (TROP2-negative) viability:5.1 µM
体外研究
(In Vitro)

Datopotamab deruxtecan solution 可特异性结合人源 TROP2。
Datopotamab deruxtecan solution 与人、食蟹猴 TROP2 的结合亲和力相近,且不与大鼠或小鼠 TROP2 结合。
Datopotamab deruxtecan (100 μg/mL;21 天) solution 在人、食蟹猴、大鼠及小鼠血浆中均保持稳定,于 37℃ 孵育 21 天后仅释放极少量 DXd (1.4%-5.5%)。
Datopotamab deruxtecan (0.32-1000 nmol/L;6 天) solution 可强效抑制 TROP2 高表达的人癌细胞系 (FaDu、BxPC-3、Caov-3、NCI-N87、CFPAC-1、HCC1806、COR-L23) 的生长,其 GI50 值为 0.48-7.8 nM,但对 TROP2 低表达的细胞系 (LK-2、Calu-6) 无抑制作用。
Datopotamab deruxtecan (10 μg/mL) solution 可高效内化至表达 TROP2 的人类癌细胞系 (BxPC-3、Caov-3、CFPAC-1、COR-L23、FaDu、HCC1806、NCI-N87) 中,在 37°C 孵育 3 小时后的平均内化率为 68.5%。
Datopotamab deruxtecan (100 nM;24 小时) solution 在与表达 TROP2 的人类癌细胞系孵育 24 小时后,释放的 DXd 量与细胞表面 TROP2 表达水平呈正相关。
Datopotamab deruxtecan (10 μg/mL;15 分钟-3 小时) solution 可时间依赖性地内化进入人胰腺癌细胞 BxPC-3,转运至核周区域,并与溶酶体标志物 LAMP-2 共定位。
Datopotamab deruxtecan (6-72 小时) solution 以时间依赖方式在人胃癌细胞 NCI-N87 中诱导 DNA 损伤 (通过 H2AX、KAP1、Chk1 的磷酸化) 和细胞凋亡 (通过 PARP 和 caspase-3 的剪切)。

Immunofluorescence

Cell Line: BxPC-3 human pancreatic cancer cells
Concentration: 10 μg/mL
Incubation Time: 15 min; 30 min; 1 h; 3 h
Result: Internalized time-dependently.
Aggregated in perinuclear regions.
Partly colocalized with the lysosomal marker LAMP-2.
体内研究
(In Vivo)

Datopotamab deruxtecan (10 mg/kg;静脉注射;单次给药) solution 通过 DXd 蓄积和诱导 DNA 损伤,在表达 TROP2 的 NCI-N87 胃癌异种移植模型中产生强效肿瘤生长抑制作用 (TGI = 96%)。
Datopotamab deruxtecan (10 mg/kg;静脉注射;单次给药) solution 可在 TROP2 高表达的 NSCLC 细胞系衍生异种移植模型中诱导强效肿瘤生长抑制作用 (TGI = 85-100%),而在 TROP2 低表达模型中无活性。
Datopotamab deruxtecan (10 mg/kg;静脉注射;单次给药) solution 在 TROP2 高表达的非小细胞肺癌患者来源异种移植物中可诱导强效肿瘤生长抑制作用 (TGI = 77-98%)。
Datopotamab deruxtecan (20-200 mg/kg;静脉注射;每 3 周 1 次,持续 3 个月) solution 在大鼠中耐受性良好,无致命性毒性,且 STD10 大于 200 mg/kg。
Datopotamab deruxtecan (10-80 mg/kg;静脉注射;每 3 周 1 次,持续 3 个月) solution 对食蟹猴的无明显毒性反应剂量 (HNSTD) 为 10 mg/kg,但当剂量 ≥30 mg/kg 时可观察到严重的肺毒性。

Animal Model: CAnN.Cg-Foxn1nu/CrlCrlj (female, athymic nude, subcutaneous inoculation of 1×107 NCI-N87 human gastric cancer cells to establish a gastric cancer xenograft model)
Dosage: 10 mg/kg
Administration: i.v.; single dose
Result: Induced significant tumor growth inhibition with a TGI of 96% (P < 0.001).
Accumulated DXd in tumor tissue, with measurable concentrations detected up to day 21 post-administration.
Observed time-dependent phosphorylation of the DNA damage marker γH2AX in tumors through day 7 post-administration.
Caused no obvious body weight loss or unforeseen events.
Animal Model: CAnN.Cg-Foxn1nu/CrlCrlj (female, athymic nude, subcutaneous inoculation of human NSCLC cell lines: 6×106 Calu-3 cells, 5×106 NCI-H2170 cells, 5×106 HCC827 cells, 1×106 LK-2 cells, 6×106 Calu-6 cells, 5×106 EBC-1 cells, to establish a lung cancer xenograft model)
Dosage: 10 mg/kg
Administration: i.v.; single dose
Result: Induced significant tumor growth inhibition in TROP2-high NSCLC models: Calu-3 (TROP2 H-score 145) with TGI of 85% (P < 0.001), NCI-H2170 (TROP2 H-score 115) with TGI of 95% (P < 0.001), HCC827 (TROP2 H-score 220) with TGI of 90% (P < 0.001), and EBC-1 (TROP2 H-score 133) with TGI of 100% (P < 0.001).
Caused no tumor growth inhibition in TROP2-low models (LK-2, TROP2 H-score 20; Calu-6, TROP2 H-score 0).
Caused no obvious body weight loss or unforeseen events.
Animal Model: Hsd:Athymic Nude-Foxn1nu (female, athymic nude, subcutaneous inoculation of patient-derived tumor fragments from NSCLC patients to establish a lung cancer xenograft model)
Dosage: 10 mg/kg
Administration: i.v.; single dose
Result: Induced significant tumor growth inhibition in all TROP2-high NSCLC patient-derived xenograft models: CTG-0163 (TROP2 H-score 262) with TGI of 77% (P < 0.001), CTG-0838 (TROP2 H-score 163) with TGI of 98% (P < 0.001), and CTG-1014 (TROP2 H-score 252) with TGI of 95% (P < 0.001).
Caused no obvious body weight loss or unforeseen events.
Animal Model: Crl:CD(SD) (male and female, healthy)
Dosage: 20 mg/kg; 60 mg/kg; 200 mg/kg
Administration: i.v.; once every 3 weeks; 3 months
Result: Caused no deaths or life-threatening toxicities at any dose tested.
Induced body weight decrease at ≥60 mg/kg.
Caused decreased white blood cells, reticulocytes, neutrophils, lymphocytes, albumin, and increased urea nitrogen at 200 mg/kg.
Induced target organ toxicities: thymus changes at ≥20 mg/kg; kidney, intestine, and incisor changes at ≥60 mg/kg; and lung, skin, bone marrow, spleen, reproductive organ changes at 200 mg/kg.
Determined the severely toxic dose in 10% of animals (STD10) was >200 mg/kg.
Animal Model: (male and female, healthy)
Dosage: 10 mg/kg; 30 mg/kg; 80 mg/kg
Administration: i.v.; once every 3 weeks; 3 months
Result: Caused no deaths at any dose tested.
Induced severe pulmonary toxicity (cell infiltration, edema, fibrosis) at ≥30 mg/kg (1 animal at 30 mg/kg, 2 animals at 80 mg/kg).
Induced body weight decrease at ≥30 mg/kg.
Induced target organ toxicities: intestinal changes at ≥10 mg/kg; lung, cornea, skin, thymus, liver changes at ≥30 mg/kg; and kidney, joint cartilage changes at 80 mg/kg.
Showed reversibility of skin and corneal lesions (except pigmentation) after treatment withdrawal.
Determined the highest non-severely toxic dose (HNSTD) to be 10 mg/kg based on pulmonary findings.
性状 液体
颜色 Colorless to light yellow

化学信息

CAS No. 2238831-60-0
别名 DS-1062 (solution); Dato-DXd (solution)

储存&溶解度

储存方式

-80°C, protect from light

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础